Emerging cardiovascular indications of mineralocorticoid receptor antagonists

Trends in Endocrinology and Metabolism

Volumn 26, Issue 4, 2015, Pages 201-211

  Parviz, Yasir ^a   Iqbal, Javaid ^b   Pitt, Bertram ^c   Adlam, David ^d   Al Mohammad, Abdallah ^a   Zannad, Faiez ^e  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF MICHIGAN   (United States)

^d GLENFIELD HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Eplerenone; Mineralocorticoid receptor; Novel indications; Spironolactone

Indexed keywords

MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; CARDIOVASCULAR AGENT; NR3C2 PROTEIN, HUMAN;

ANGIOPLASTY; AORTA VALVE DISEASE; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG SCREENING; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SUDDEN CARDIAC DEATH; TREATMENT INDICATION; VALVULAR HEART DISEASE; AGONISTS; ANIMAL; ARRHYTHMIAS, CARDIAC; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; CHEMISTRY; DEATH, SUDDEN, CARDIAC; DISEASE COURSE; HYPERTENSION, PULMONARY; METABOLISM; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DEATH, SUDDEN, CARDIAC; DISEASE PROGRESSION; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MODELS, BIOLOGICAL; OFF-LABEL USE; RECEPTORS, MINERALOCORTICOID; SEVERITY OF ILLNESS INDEX;

EID: 84933678746     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.01.007     Document Type: Review

References (74)

1. Funder J.W. Mineralocorticoid receptors: distribution and activation. Heart Fail. Rev. 2005, 10:15-22.
2. Fuller P.J., Young M.J. Mechanisms of mineralocorticoid action. Hypertension 2005, 46:1227-1235.
3. Struthers A., et al. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin. Cardiol. 2008, 31:153-158.
4. Iqbal J., et al. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur. J. Heart Fail. 2014, 16:143-150.
5. Fagart J., et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J. Biol. Chem. 2010, 285:29932-29940.
6. Pitt B., et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur. J. Heart Fail. 2012, 14:668-675.
7. Martin-Fernandez B., et al. Beneficial effects of proanthocyanidins in the cardiac alterations induced by aldosterone in rat heart through mineralocorticoid receptor blockade. PLoS ONE 2014, 9:e111104. Published online October 29, 2014. http://dx.doi.org/10.1371/journal.pone.0111104.
8. Pitt B., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999, 341:709-717.
9. Zannad F., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011, 364:11-21.
10. Pitt B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348:1309-1321.
11. Pitt B., et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 2013, 34:2453-2463.
12. Montalescot G., et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur. Heart J. 2013, 35:2295-2302. Published online April 29, 2014. http://dx.doi.org/10.1093/eurheartj/ehu164.
13. Beygui F., et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am. Heart J. 2010, 160:642-648.
14. Croom K.F., Perry C.M. Eplerenone: a review of its use in essential hypertension. Am. J. Cardiovasc. Drugs 2005, 5:51-69.
15. Chapman N., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
16. Pitt B., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831-1838.
17. Flack J.M., et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. 2003, 41:1148-1155.
18. Hollenberg N.K., et al. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch. Internal Med. 2003, 163:1543-1548.
19. Brilla C.G., et al. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell Cardiol. 1993, 25:563-575.
20. Sato A., et al. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens. Res. 1999, 22:17-22.
21. Mansia G., et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007, 16:135-232.
22. Mak G.J., et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J. Am. Coll. Cardiol. 2009, 54:1674-1682.
23. Deswal A., et al. Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). J. Card. Fail. 2011, 17:634-642.
24. Patel K., et al. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2013, 1:40-47.
25. Kosmala W., et al. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc. Imaging 2011, 4:1239-1249.
26. Edelmann F., et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur. J. Heart Fail. 2010, 12:874-882.
27. Pitt B., et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 2014, 370:1383-1392.
28. Martyniuk T.V., et al. [Activity of renin-angiotensin-aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension]. Ter. Arkh. 1998, 70:33-36.
29. Yamanaka R., et al. Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension. Hypertens. Res. 2010, 33:435-445.
30. Maron B.A., et al. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 2012, 126:963-974.
31. Maron B.A., et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am. J. Cardiol. 2013, 112:720-725.
32. Pei D.A., et al. [Study on expression of mineralocorticoid receptor in human atria during atrial fibrillation]. Zhonghua Xin Xue Guan Bing Za Zhi 2007, 35:114-118.
33. Lavall D., et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J. Biol. Chem. 2014, 289:6656-6668.
34. Reil J.C., et al. Aldosterone promotes atrial fibrillation. Eur. Heart J. 2012, 33:2098-2108.
35. Goette A., et al. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am. J. Cardiol. 2001, 88:906-909. A8.
36. Milliez P., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 2005, 45:1243-1248.
37. Yang S.S., et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chinese Med. J. 2008, 121:38-42.
38. Zhao J., et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br. J. Pharmacol. 2010, 159:1584-1594.
39. Shroff S.C., et al. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J. Cardiovasc. Electrophysiol. 2006, 17:534-541.
40. Williams R.S., et al. Effect of spironolactone on patients with atrial fibrillation and structural heart disease. Clin. Cardiol. 2011, 34:415-419.
41. Ito Y., et al. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. Am. J. Cardiol. 2013, 111:1012-1018.
42. Swedberg K., et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J. Am. Coll. Cardiol. 2012, 59:1598-1603.
43. Dabrowski R., et al. Effect of combined spironolactone-beta-blocker +/- enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am. J. Cardiol. 2010, 106:1609-1614.
44. Ouvrard-Pascaud A., et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005, 111:3025-3033.
45. Wei J., et al. The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis. Clin. Cardiol. 2010, 33:572-577.
46. Beck L., et al. Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. Cardiology 2001, 96:85-93.
47. Rocha R., et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451-458.
48. Michea L., et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension 2008, 52:295-300.
49. Chua D., et al. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?. Clin. Cardiol. 2010, 33:604-608.
50. Matsumoto Y., et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J. Am. Coll. Cardiol. 2014, 63:528-536.
51. Edwards N.C., et al. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br. J. Clin. Pharmacol. 2012, 73:447-454.
52. Pitt B., Rossignol P. Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis. J. Am. Coll. Cardiol. 2014, 63:537-538.
53. Guo C., et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008, 117:2253-2261.
54. Armani A., et al. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J. 2014, 28:3745-3757.
55. Stiefel P., et al. Role of the renin-angiotensin system and aldosterone on cardiometabolic syndrome. Int. J. Hypertens. 2011, 2011:685238. Published online June 23, 2011. http://dx.doi.org/10.4061/2011/685238.
56. McGraw A.P., et al. Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. J. Am. Heart Assoc. 2013, 2:e000018. Published online February 22, 2013. http://dx.doi.org/10.1161/JAHA.112.000018.
57. de Rita O., et al. Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can. J. Cardiol. 2012, 28:706-711.
58. Yamaji M., et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1)(c) levels in patients with chronic heart failure. Am. Heart J. 2010, 160:915-921.
59. Joffe H.V., et al. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J. Clin. Endocrinol. Metab. 2007, 92:2552-2558.
60. Alderman M.H., et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N. Engl. J. Med. 1991, 324:1098-1104.
61. Brown N.J., et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998, 32:965-971.
62. Ward M.R., et al. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001, 104:467-472.
63. Van Belle E., et al. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc. Res. 1995, 29:27-32.
64. Kursaklioglu H., et al. Spironolactone does not prevent restenosis after coronary stenting in humans. Ann. Acad. Med. Singapore 2004, 33:769-774.
65. Wakabayashi K., et al. Eplerenone suppresses neointimal formation after coronary stent implantation in swine. Int. J. Cardiol. 2006, 107:260-266.
66. Iqbal J., et al. Contribution of endogenous glucocorticoids and their intravascular metabolism by 11beta-HSDs to postangioplasty neointimal proliferation in mice. Endocrinology 2012, 153:5896-5905.
67. Iqbal J., et al. Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial. Eur. J. Heart Fail. 2014, 16:685-691.
68. Stewart R.A., et al. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. Am. Heart J. 2008, 156:348-355.
69. Zendaoui A., et al. Effects of spironolactone treatment on an experimental model of chronic aortic valve regurgitation. J. Heart Valve Disease 2012, 21:478-486.
70. Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol. Cell. Endocrinol. 2004, 217:45-52.
71. Dorrance A.M., et al. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am. J. Physiol. Regul. Integr. Compar. Physiol. 2001, 281:R944-R950.
72. Iwanami J., et al. Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. Eur. J. Pharmacol. 2007, 566:153-159.
73. Frieler R.A., et al. Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke 2011, 42:179-185.
74. Tomaschitz A., et al. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur. Heart J. 2010, 31:1237-1247.